Skip to main content
. 2018 Apr 24;9(31):21930–21942. doi: 10.18632/oncotarget.25128

Figure 1. EZH2 inhibition induces H3K27 demethylation in all HMCLs and decreases viability in a subset of HMCLs.

Figure 1

(A) A panel of 14 HMCLs were treated with a concentration range of EZH2 inhibitors EPZ-6438 and GSK-126 for either 4 or 9 days. Viability was measured with CellTiter-Glo® (Promega) assays and normalized to untreated controls. (B) H3K27 demethylation was quantified after a 6 day treatment with a range of EZH2 inhibitors in two EZH2i-sensitive (FLAM76 and SKMM2) and two EZH2i-resistant (MMM1 and H929) HMCLs. H3K27me3 was quantified by western blot where total histone 3 (mouse anti-H3; CST#3638) and H3K27me3 (rabbit anti-H3K27me3; CST#9733) were simultaneously quantified via a LI-COR® fluorescence reader. Relative densitometry (C) was calculated for each EZH2i concentration and normalized to the untreated control. All error bars represent SEM between biological replicates.